Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
Such generic drugs could save nations huge sums in the coming years.
Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.
Epivir (lamivudine) and Viread (tenofovir) are likely safe for women to use while breast-feeding.
Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...
The HIV antiretroviral Viread (tenofovir) is highly effective in combating both HIV and hepatitis B among those coinfected with both viruses
Viread (tenofovir) and Epivir (lamivudine) lower the risk of infection with hepatitis B among HIV-positive gay men who havenâ€™t been vac...
About 12 percent of HIV-positive people with chronic hepatitis B virus (HBV) infection failed to control their HBV after one year with Viread...
Gilead Sciences announced earlier this week that the U.S. Food and Drug Administration has approved Viread for the treatment of chronic hepa...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.